Vivos Therapeutics, Inc. — Form 10-Q
Filed November 16, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 8/100
What the filing says
This is a Form 10-Q for Vivos Therapeutics (market cap ~$22.9M) for the period ending September 30, 2026, filed November 16, 2026. The document index lists 85 exhibits but the actual financial statements, MD&A, and business developments are not included in the text provided—only the filing header and XBRL schema files are shown. No specific financial metrics, transactions, counterparties, dollar amounts, or material events are disclosed in the submitted text.
Why this rating
Cannot assess significance without substantive filing content. Routine quarterly report filing; lack of disclosed details prevents material event analysis.
See more from November 16, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.